{"name":"EdiGene Inc.","slug":"edigene-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATHENA CAR-T","genericName":"ATHENA CAR-T","slug":"athena-car-t","indication":"Relapsed or refractory B-cell acute lymphoblastic leukemia","status":"phase_1"}]}],"pipeline":[{"name":"ATHENA CAR-T","genericName":"ATHENA CAR-T","slug":"athena-car-t","phase":"phase_1","mechanism":"CAR-T cell therapy targeting CD19","indications":["Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOMXA0Um15WHZ1UnQzQ2M1OFVqUXdDdVk3YUxYeXNlenNWdmFSeEIwODZlWWtpNkw5Ny1EUGdZU045aDlRSTZOeU1YYUI4cXl3RVFtUEZpdUxRVm1iS0g2QUw5R2tUQ1g3X0ZiT1EyNlJKRUNNR2s4RTFTN0VqcElzSU5QcmJ5YWR2WG9KSXdiYlQtY1ZncFRF?oc=5","date":"2026-04-08","type":"trial","source":"openPR.com","summary":"Mucopolysaccharidosis Type I Clinical Trial and Pipeline - openPR.com","headline":"Mucopolysaccharidosis Type I Clinical Trial and Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTGhucUthb1NKd2Y0Umw2UjlvY0lEZ05Xa08tZk5VVjA2RTYtRVBfYW56dENkLXgwb0J0WDJpRGVTQ3BUSTBmRHFJSmdyR1BaUFBaeDQxSjE5TGgwbWRRUms1Nm5LMl91UzdvRmsyZXRSMXptRWtpY2p0dkdqWDJhODlaNXVLT3hLY21qb25vX29VclIz?oc=5","date":"2026-03-24","type":"pipeline","source":"openPR.com","summary":"Mucopolysaccharidosis Type I Pipeline 2026: MOA and ROA - openPR.com","headline":"Mucopolysaccharidosis Type I Pipeline 2026: MOA and ROA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFAtb1JRMmxVaV9IOU5wZ3hYWmxkXzdkTUdiQ3lHTWNoYklGV0dKQW5MT2FQdmF2b2cxQ3JSWm1XUVpOaUVtZTUzdWVRdVFra3dSc3htYjItZHdNRjRBa0RCbkxSMzJVZU8yUHhTTFQ0aEpfSUdaTE9qaGg0RFBpdw?oc=5","date":"2026-03-14","type":"pipeline","source":"China Daily","summary":"China advances biotech innovation: Expert - China Daily","headline":"China advances biotech innovation: Expert","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPYTBCUzJmNGN5WHZ0VFM5aThrNzdDeVhtdDJMRDVXVEtzTGN1M0FyVkVtMEpGWVpTUmJTd3RKN2dBYzM3RDZ0WHpNbUMxN2d3eVpRelR4MXdVRGMySGJzZk9qZ215WkJoS0x1Yzk4dDI0VTVGX21lUDNyYVg4bHd5Q3BoYkpUVVh5?oc=5","date":"2025-03-17","type":"pipeline","source":"statnews.com","summary":"These 12 Chinese companies are poised to transform CRISPR gene-editing - statnews.com","headline":"These 12 Chinese companies are poised to transform CRISPR gene-editing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOckRlekJZNXlldy1wX3lUWk5pSXFmTkM4dkZxMVUwSVVBeGdvN1FXQkRrN3VUMXdpeTdpSHp5NmZDRGszelo1NG83LU0xSERRWkhiN0FNYkZlMTB3V2ZnRm9mdVZ3dGp3b3NvWkdzLTQzZEFvMlBNSGltU1dPMlZQVDVjRDh0OFlNVU5Ba0NSWjVac05hdWhHcm04VFhpTHpyOER5WjI3NA?oc=5","date":"2024-05-31","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Top Five Privately Held Gene Editing Therapy Companies - Genetic Engineering and Biotechnology News","headline":"Top Five Privately Held Gene Editing Therapy Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQRGowd0t1WHN4X2p5MmdfWU1ET01VdDBRdkVCZkFjTmxTeklFbTN0bWZYMTlUeVhYSXUxTnRGeFdnOV9VZUtkSnVCRjJ6RTlJWHpiakpwVjV5MGJvWGhBWXc5V292dUZFNUxlMjZ6SF9BZmNTOEllQkZvTlYyOFJwMmdpSFhFR2RKN3RaV2VMcno4TTRMS09WYkQwUng?oc=5","date":"2023-07-26","type":"pipeline","source":"CRISPR Medicine News","summary":"Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News","headline":"Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxPVWs4MnV6bC1jT21VWTZWTXZjNk13dU13RHpCdUFFYl82bGNiRE9oY2hJb0ktb3Fya2IzclQtalUxWGM3a09pWld6NG5JTjJobDl2ejlfUWNnbHBMVXFIeFpsd3pGX3JNTGpmMUZ3VC1wZThsWGo0SER3RURDa01oMEhxcXl0bzlMdFlHS3BsX2o3WFhYcEY4N0Y2V0FGUVJTbS1CYjBZY0VxcFpMaHNGS24wUC1fWEFhcHo1aVRWR1B3bEtRM3ZEbElSLTM1c0JESE9TR1dSckNveFdFclpBTnZUOXItVl9Sd3R3LWM5WEM0ckxsbmZTZDlFdF9qRzhBMFJhclZHOTNQR1dVTUpNem1RRXpuWm1iRkxxV0F5SVdlQjYyVlJpeUhGTnBWLTRSZ1RkbDd3?oc=5","date":"2022-11-07","type":"pipeline","source":"Business Wire","summary":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies - Business Wire","headline":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transfo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNLWpaUDdqZ0JyamdPaFdyc185T3R1R3NYenZjMUJoZlp5SENDOVhiRnpDM3VvMGMyZlh6cE1HeHNqV1BoRlM1WlFQS1ZKX0ZLMnBhRjhhU3BVaTN2cktCczhCOEIxWEliRlM3OC1FTzEtMno1VUMyNmtNSHBZakRpU3piQ0p1TVkwbFZyS1VIb3hTeTRGUVpZSnAxUG8tWXNfejQ0TEUtS25lZGRyVEJzWm5PMWNva1BReTEwcmNnemNkajR0VjdVMEZQQ2h1OGNLX1E?oc=5","date":"2021-09-15","type":"trial","source":"CRISPR Medicine News","summary":"Clinical Update: EdiGene Enrols First Patient in Phase 1 Trial for Transfusion-Dependent Beta Thalassemia - CRISPR Medicine News","headline":"Clinical Update: EdiGene Enrols First Patient in Phase 1 Trial for Transfusion-Dependent Beta Thalassemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQUnVkWVl0YnhrcFFhcDd3ZGl1d0hqXzdPMXhuZ0VURVhWQVVKSGllY0p1RGRoeGowMzhYRzBSb1dVaGNER0RpdktzMEFYaU81NGk0VXpQeVdiVGdxZk42Z2ZzTm40S1VYa2RaTmNWUkg2RHZMT0pwelRMS0pxaDluaktVNmFxYVZrYXRaZjZ2LW9FdFQ2aV9RaTBLMlpIMDhYcWFfVHBJNXBRMV96T2lBbEg1LUZRMDFPNVhzTFZWYWFKOG9GVUtneEFicW9aLURzLXAyZDN0REZRTFV2alBXYWw1WU9PUzkyZmQzVk82NVFSYlFLdDlkTzZBVlBmVWZsZjJZVVpMdWREMHBmWlE?oc=5","date":"2020-10-13","type":"pipeline","source":"Business Wire","summary":"EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage - Business Wire","headline":"EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical S","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}